These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11101088)

  • 21. [Molecular changes in development and progression of urothelial carcinoma].
    Hartmann A
    Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects.
    Miyake H; Hara I; Fujisaw M; Gleave ME
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1001-9. PubMed ID: 16336091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenovirus-mediated gene therapy for bladder cancer: efficient gene delivery to normal and malignant human urothelial cells in vitro and ex vivo.
    Chester JD; Kennedy W; Hall GD; Selby PJ; Knowles MA
    Gene Ther; 2003 Jan; 10(2):172-9. PubMed ID: 12571646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions.
    Schwarz S; Rechenmacher M; Filbeck T; Knuechel R; Blaszyk H; Hartmann A; Brockhoff G
    J Clin Pathol; 2008 Mar; 61(3):272-7. PubMed ID: 17693577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene expression profile in squamous cell carcinoma of the urinary bladder using complementary deoxyribonucleic acid microarray.
    Ewis AA; El-Samman E; Ali N; Kajimoto K; Shinohara Y; Ishikawa M; Kanayama HO; Baba Y
    Urol Oncol; 2007; 25(2):120-7. PubMed ID: 17349526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H; Reiter RR; Ravaud A
    Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation-dependent localisation of tissue-type plasminogen activator in human bladder urothelium.
    Makuc J; Masera A; Trsinar B; Jezernik K
    Cell Biol Int; 2004; 28(5):381-6. PubMed ID: 15193281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Identification of gene expression patterns in superficial and invasive human bladder cancers].
    Zhou L; Shi BT; Wang SX; Luo Y; Yang L; Zhang LL; Wang XY; He DL
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(12):798-801. PubMed ID: 17565857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification.
    Mitra AP; Datar RH; Cote RJ
    J Clin Oncol; 2006 Dec; 24(35):5552-64. PubMed ID: 17158541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo retroviral mediated gene transfer into bladder urothelium results in preferential transduction of tumoral cells.
    Dumey N; Mongiat-Artus P; Devauchelle P; Lesourd A; Cotard JP; Le Duc A; Marty M; Cussenot O; Cohen-Haguenauer O
    Eur Urol; 2005 Feb; 47(2):257-63. PubMed ID: 15661423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene therapy in bladder cancer.
    Bochner BH
    Curr Opin Urol; 2008 Sep; 18(5):519-23. PubMed ID: 18670278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
    Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
    Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
    Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
    Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder cancer: modeling and translation.
    Rosenberg JE; Hahn WC
    Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.
    Nativ O; Dalal E; Hidas G; Aronson M
    Int J Urol; 2006 Oct; 13(10):1344-6. PubMed ID: 17010016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudocarcinomatous epithelial hyperplasia in the bladder unassociated with prior irradiation or chemotherapy.
    Lane Z; Epstein JI
    Am J Surg Pathol; 2008 Jan; 32(1):92-7. PubMed ID: 18162775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromosomal and proteome analysis of a new T24-based cell line model for aggressive bladder cancer.
    Makridakis M; Gagos S; Petrolekas A; Roubelakis MG; Bitsika V; Stravodimos K; Pavlakis K; Anagnou NP; Coleman J; Vlahou A
    Proteomics; 2009 Jan; 9(2):287-98. PubMed ID: 19105184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiling of responses to dimethylarsinic acid in female F344 rat urothelium.
    Sen B; Wang A; Hester SD; Robertson JL; Wolf DC
    Toxicology; 2005 Nov; 215(3):214-26. PubMed ID: 16122865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical management of bladder cancer in 2003.
    Wade M; Seigne JD
    Expert Rev Anticancer Ther; 2003 Dec; 3(6):781-92. PubMed ID: 14686700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.